Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas

Laryngoscope

Volumn 119, Issue 8, 2009, Pages 1542-1549

  Sedaghat, Ahmad R ^a   Zhang, Zhe ^b   Begum, Shahnaz ^a   Palermo, Robert ^c   Best, Simon ^b   Ulmer, Karen M ^c   Levine, Marshall ^c   Zinreich, Eva ^c   Messing, Barbara P ^c   Gold, Dorothy ^c   Wu, Annie A ^a   Niparko, Kevin J ^a   Kowalski, Jeanne ^b   Hirata, Richard M ^a   Saunders, John R ^a,c   Westra, William H ^a,b   Pai, Sara I ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

Head and neck cancer; Human papilloma virus (HPV); Oropharynx

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; CLINICAL PROTOCOL; DEMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MORTALITY; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT; VIRUS DETECTION; WART VIRUS;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 68849104547     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20533     Document Type: Article

References (25)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-1709.
2. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-1956.
3. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck- Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. lnt J Cancer 2000;89:300-304.
4. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001;125:1-9.
5. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer lnst 2008;100:261-269.
6. Hafkamp HC, Manni JJ, Speel EJ. Role of human papillo- mavirus in the development of head and neck squamous cell carcinomas. Acta Otolaryngol 2004;124:520-526.
7. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 1997;79:595-604.
8. Venuti A, Badaracco G, Rizzo C, Mafera B, Rahimi S, Vigili M. Presence of HPV in head and neck tumours: high prevalence in tonsillar localization. J Exp Clin Cancer Res 2004;23:561-566.
9. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804.
10. Kerstens HM, Poddighe PJ, Hanselaar AG. A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. J Histochem Cyto- chem 1995;43:347-352.
11. Huang CC, Qiu JT, Kashima ML, Kurman RJ, Wu TC. Generation of type-specific probes for the detection of single- copy human papillomavirus by a novel in situ hybridization method. Mod Pathol 1998;11:971-977.
12. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541-554.
13. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1988;16:1141-1154.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
15. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007;110:1429-1435.
16. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005;103:1843-1849.
17. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-2561.
18. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630-5636.
19. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. lnt J Cancer 2007;120:1731-1738.
20. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus-associ- ated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24:736-747.
21. Li W, Thompson CH, O'Brien CJ, et al. Human papilloma- virus positivity predicts favourable outcome for squa- mous carcinoma of the tonsil. lnt J Cancer 2003;106:553-558.
22. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92:805-813.
23. Cmelak AJ, Li S, Goldwasser MA, et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oro- pharynx: results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 2007;25:3971-3977.
24. Hodge CW, Bentzen SM, Wong G, et al. Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. lnt J Radiat Oncol Biol Phys 2007;69:1032-1041.
25. Ballonoff A, Chen C, Raben D. Current radiation therapy management issues in oral cavity cancer. Otolaryngol Clin North Am 2006;39:365-380.